Medical Image Analysis Software Market worth $6.42 billion by 2031 - Exclusive Report by MarketsandMarkets™

The medical image analysis software market is projected to grow from $4.35B in 2026 to $6.42B by 2031 (8.1% CAGR), with AI-enabled technology set to post the fastest growth (8.6% CAGR) and already representing 58.7% of the market in 2025. Growth is supported by rising imaging volumes (~5% annually in the US) and radiologist shortages (only ~1,000 new radiologists entering each year vs ~1,900 job postings in Jan 2025), but adoption is tempered by high validation costs and data/privacy and legacy PACS/RIS integration challenges. Deal momentum is notable, including GE HealthCare’s $2.3B acquisition of Intelerad (completed March 2026) and RadNet’s ~$264.1M acquisition of Gleamer, reinforcing investor and industry expectations for consolidation around AI and workflow platforms.

Analysis

This is more a distribution and workflow story than a pure AI TAM story. The economic value should accrue to vendors already embedded in scanner fleets, PACS, and hospital procurement, because they can bundle AI into refresh cycles and convert software into recurring revenue with far lower customer-acquisition cost than standalone radiology AI startups. That favors GEHC first, PHG second, and leaves most pure-play vendors fighting for niche workflows and pilot budgets rather than enterprise rollouts.

The near-term catalyst is not the market-size estimate itself but evidence of attach-rate: software mix, recurring revenue, and commentaries on deal conversion at the next earnings cycles over the next 1-3 months. Over 6-18 months, regulation should act as a moat for incumbents because compliance, validation, and data-governance costs scale nonlinearly with vendor count; smaller hospitals may still delay adoption, but the burden of proving safety should consolidate share toward large OEMs. MSFT is an upstream enabler, but value capture is likely diluted versus healthcare OEMs unless Azure becomes the default imaging workflow layer.

The consensus may be overestimating how quickly AI radiology turns into revenue and underestimating how much of the benefit is defensive rather than incremental. If reimbursement stays inconsistent, hospitals will prioritize triage and decision-support tools over full diagnostic automation, which caps wallet share and slows the re-rating for software-only names. Falsifiers: GEHC or PHG showing no software mix improvement and no order acceleration into the next print, or any evidence that standalone vendors are winning enterprise deployments faster than expected.

Key Decisions for Investors

• Long GEHC on pullbacks over the next 1-3 months; best risk/reward is a call-spread structure into the next earnings cycle, with upside tied to software attach-rate commentary. Falsify if imaging/software revenue fails to inflect or if order backlog softens.
• Relative-value long GEHC / short PHG for the next 1-2 quarters. Thesis: GEHC has a cleaner workflow-software monetization path and better M&A integration optionality; cover if PHG shows faster AI-driven mix expansion or stronger U.S. commercial traction.
• Do not chase MSFT as a direct beneficiary; treat it as an upstream infrastructure proxy only. If used at all, keep it as a small hedge against healthcare AI beta rather than a standalone expression.
• Set an alert for EU AI Act and FDA commercialization updates over the next 1-3 months. A quicker-than-expected compliance burden should accelerate consolidation and strengthen GEHC/PHG; any reimbursement delay or hospital procurement freeze would argue to reduce exposure.